Anticancéreux: le prix maximal toléré a-t-il été atteint ? = Anticancer agents: has the maximal tolerated price been reached?LEVEQUE, Dominique.Bulletin du cancer. 2012, Vol 99, Num 9, pp 808-810, issn 0007-4551, 3 p.Article

PHENOTYPIC EXPRESSION OF DRUG RESISTANCE IN HYBRID CELLSHARRIS M.1973; J. NATION. CANCER INST.; U.S.A.; DA. 1973; VOL. 50; NO 2; PP. 423-429; BIBL. 29REF.Serial Issue

ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS. I. BIOCHEMICAL AND CLINICAL PHARMACOLOGICAL CONSIDERATIONS = MEDICAMENTS ANTINEOPLASIQUES ET IMMUNODEPRESSEURS. I. CONSIDERATIONS BIOCHIMIQUES ET DE PHARMACOLOGIE CLINIQUE1972; DRUGS; SWITZ.; DA. 1972; VOL. 3; NO 3-4; PP. 227-253; BIBL. 4 P.Serial Issue

Reevaluating the Accelerated Approval Process for Oncology DrugsWILSON, Wyndham H; SCHENKEIN, David P; JERNIGAN, Cheryl L et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 2804-2809, issn 1078-0432, 6 p.Article

Hydrallmanol A, an interesting diphenyl-p-menthane derivative of mixed biogenetic origin from the hydroid Hydrallmania falcataPATHIRANA, C; ANDERSEN, R. J; WRIGHT, J. C. L et al.Tetrahedron letters. 1989, Vol 30, Num 12, pp 1487-1490, issn 0040-4039, 4 p.Article

Vindesine and high-dose cisplatin in the treatment of advanced non-small-cell lung cancerFUKS, J. Z; PATEL, H; VAN ECHO, D. A et al.Medical and pediatric oncology. 1985, Vol 13, Num 2, pp 73-77, issn 0098-1532Article

Antineoplastic activity of esters and amides of N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-aminoacidsZELLER, W. J; EHRESMANN, K; EISENBRAND, G et al.Journal of cancer research and clinical oncology. 1984, Vol 108, Num 2, pp 249-251, issn 0171-5216Article

DrugsCancer chemotherapy. 1984, Num 6, pp 1-199Article

Determination of panaxytriol, a new type of tumour growth inhibitor from Panax ginseng, by capillary gas chromatographyMATSUNAGA, H; KATANO, M; YAMAMOTO, H et al.Journal of chromatography. 1989, Vol 481, pp 368-372, issn 0021-9673, 5 p.Article

Tricyclic heteroatomatic systems. 1,2,3,4-tetrahydropyrazolo[4,3-c][1]benzazepin-1-ones as potential antitumor agentsPALAZZINO, G; CECCHI, L; COLOTTA, V et al.Journal of heterocyclic chemistry. 1989, Vol 26, Num 1, pp 71-75, issn 0022-152X, 5 p.Article

Effects of clinical combinations of antileukemic drugs on DNA ligase from human thymocytes and normal, stimulated, or leukemic lymphocytesLAMBALLE, F; MANIEY, D; BOSCHER, M.-Y et al.Leukemia. 1988, Vol 2, Num 6, pp 363-370, issn 0887-6924Article

Differential reactivity of 9-NH₂-ellipticine on apurinic and apyrimidinic sites in circular DNAMALVY, C; BERTRAND, J. R.FEBS letters. 1986, Vol 208, Num 1, pp 155-157, issn 0014-5793Article

Analytical DNA flow cytometric analysis of deoxyadenosine toxicity in cultured human leukemic lymphoblastsFOX, R. M; TRIPP, E. H; TAYLOR, I. W et al.Molecular pharmacology. 1984, Vol 26, Num 2, pp 388-394, issn 0026-895XArticle

Pharmacological investigations on lodinamineCIOLI, V; CORRADINO, C; DE MARTINO, C et al.Arzneimittel-Forschung. 1984, Vol 34, Num 4, pp 455-460, issn 0004-4172Article

Ultrastructural observations on the vincristine-induced neuronal crystalloid inclusion in young ratsSATO, M; MIYOSHI, K.Acta neuropathologica. 1984, Vol 63, Num 2, pp 150-159, issn 0001-6322Article

The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor β1 (TGF-β1) : IV meeting of the inter-regional group Abruzzo, Lazio, Molise, Toscana, Umbria of the Italian Society of Pharmacology, Pisa, March 11, 1991DANESI, R; AGEN, C; BERNARDINI, N et al.Pharmacological research. 1992, Vol 25, pp 17-18, issn 1043-6618, SUP1Conference Paper

Circadian tolerance to etoposide and cisplatin as first line treatment for advanced lung carcinomaFOCAN, C; BASTENS, B; DRIESSCHAERT, P et al.Annual review of chronopharmacology. 1990, Vol 7, pp 219-222, issn 0743-9539, 4 p.Conference Paper

The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dthdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd) following infusion of FUra or FdUrdDAHER, G. C; HARRIS, B. E; ZHANG, R.-W et al.Annual review of chronopharmacology. 1990, Vol 7, pp 227-230, issn 0743-9539, 4 p.Conference Paper

A ¹H n.m.r. study of the role of the glutamate moiety in the binding of methotrexate to Lactobacillus casei dihydrofolate reductaseANTONJUK, D. J; BIRDSALL, B; CHEUNG, H. T. A et al.British journal of pharmacology. 1984, Vol 81, Num 2, pp 309-315, issn 0007-1188Article

Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengersMIMNAUGH, E. G; GRAM, T. E; TRUSH, M. A et al.The Journal of pharmacology and experimental therapeutics. 1983, Vol 226, Num 3, pp 806-816, issn 0022-3565Article

Structure-activity relationships for binding and inactivation of rabbit reticulocyte ribosomes by quassinoid antineoplastic agentsCONSIDINE, R. T; WILLINGHAM, W. JR; GHANEY, S. G et al.European journal of biochemistry (Print). 1983, Vol 132, Num 1, pp 157-163, issn 0014-2956Article

Chronotoxicity and phenotypic variabilityASHKENAZI, I. E; PELEG, L; COHEN-KITAY, Y et al.Annual review of chronopharmacology. 1990, Vol 7, pp 241-244, issn 0743-9539, 4 p.Conference Paper

Sparsomycin analogs. VI: Synthesis and antitumor activity of octylsparsomycin analogsKANATOMO, S; HASE, T; WADA, A et al.Chemical and pharmaceutical bulletin. 1989, Vol 37, Num 3, pp 688-691, issn 0009-2363, 4 p.Article

Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopyLOWN, J. W; HANSTOCK, C. C; BRADLEY, R. D et al.Molecular pharmacology. 1984, Vol 25, Num 1, pp 178-184, issn 0026-895XArticle

Anti-tumor effect of new 5-fluorouracil derivatives and their influences on the immune responseMORI, H; NAKATOMI, I; KATO, Y et al.Japanese journal of pharmacology. 1983, Vol 33, Num 6, pp 1205-1214, issn 0021-5198Article